Trials / Unknown
UnknownNCT04776512
Erector Spinae Plane Block Versus Classic Epidural Analgesia in Labor
Lumbar Erector Spinae Plane Block Versus Classic Epidural Analgesia in Labor
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Mongi Slim Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prosepective,Randomized, controlled study enrolling full termed parturients admitted for vaginal delivery. At the sencond stage of labor: 3cm of cervix dilatation, patients will be randomized in 2 groups: * ESP group: patients will receive ultrasound guided, bilateral ESP Block performed at the level of the 3 rd Lumbar transverse process. * Epidural Analgesia Group: Patients will have a classic lumbar continuous epidural analgesia.
Detailed description
Prosepective,Randomized, controlled study enrolling full termed parturients admitted for vaginal delivery. At the sencond stage of labor: 3cm of cervix dilatation, patients will be randomized in 2 groups: * ESP group: patients will receive ultrasound guided, bilateral ESP Block performed at the level of the 3 rd Lumbar transverse process. * Epidural Analgesia Group: Patients will have a classic lumbar continuous epidural analgesia. For the first group: 20 ml of 0,375% isobaric Bupivacain solution will be injected bilaterally under ultrasound direct vision. Concerning the second group, patients will have a continuous injection of 0,125% Bupivacain solution associated to 0,25 mcg of Sufentanil/ml through an epidural catheter in the L3-L4 or L4-L5 intervertebral space. For the 2 groups, analgesia will be assessed during all the labor period hourly using the Visual Analog pain Score (VAS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | ESP Block With Bupivacain | bilateral lumbar ESP block using 0.375% Bupivacain |
| PROCEDURE | Epidural Analgesia | Continuous Lumbar Epidural analgesia With 0,125% Bupivacain+0,25 mcg/ml Sufentanil |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2021-06-30
- Completion
- 2021-07-31
- First posted
- 2021-03-01
- Last updated
- 2021-03-01
Source: ClinicalTrials.gov record NCT04776512. Inclusion in this directory is not an endorsement.